A prospective study of ultrasound scan-guided thrombin injection of femoral pseudoaneurysm: A trend toward minimal medication  by Olsen, Dawn M. et al.
A prospective study of ultrasound scan–guided
thrombin injection of femoral pseudoaneurysm: A
trend toward minimal medication
Dawn M. Olsen, PA-C, MMSc, Julio A. Rodriguez, MD, Mitar Vranic, DO, Venkatesh Ramaiah, MD,
Rajogopalan Ravi, MD, and Edward B. Diethrich, MD, Phoenix, Ariz
Background: Catheterizations and endovascular procedures in which the femoral artery is cannulated are sometimes
complicated by iatrogenic pseudoaneuryms. Surgical repair of pseudoaneurysms was the treatment of choice until 1991
when compression was used in those that were small. A less uncomfortable technique involving the ultrasound
scan–guided injection of thrombin (UGTI) has been used more recently. The purpose of this study was to prospectively
evaluate the effectiveness of ultrasound scan–guided thrombin injection (UGTI) as a treatment of iatrogenic femoral
pseudoaneurysms.
Methods: From December 1998 to December 2000, 3734 femoral artery catheterizations were performed, and from those,
32 consecutive patients with 33 femoral pseudoaneurysms (0.88%) of less than 8 cm were prospectively enrolled for
UGTI. With sterile technique, a 21-gauge or 22-gauge spinal needle was used to access the pseudoaneurysm and
thrombin (100 to 6000 international units [IU]) was slowly injected until thrombosis occurred.
Results: The initial success rate was 100%. Thirty-one cases (93.9%) remained successfully thrombosed with a single
injection at day 30. Recurrence of two pseudoaneurysms (6.1%) was seen at day 1 and day 8. One patient had groin
cellulitis develop, and the other had a bleed into the thigh after discharge; both were treated with open surgical repair.
Fifteen patients underwent UGTI on an outpatient basis with 100% successful ablation. More than half of the patients
were on an inpatient basis (53.1%). Hospital stay was 1 to 9 days, with 88.2% of the patients released on day 1 or 2.
However, two patients had a prolonged stay: one from open repair (day 9) and the other from a gastrointestinal bleed
(day 8). Pseudoaneurysms ranged from 1.7 to 7.5 cm and lasted 1 to 17 days before UGTI. Twenty-one of the patients
(65.7%) continued undergoing anticoagulant therapy at the time of injection. Ten of the last 11 cases needed less than 800
IU, and nearly half of the pseudoaneurysms (49%) successfully thrombosed with less than 600 IU. No procedural
complications or mortality were noted. No statistical significance was found between occurrence of the pseudoaneurysm
and sheath size (with 2 test, P value  .05) or between the size of the pseudoaneurysm and successful thrombosis (with
2 test: degrees of freedom, 6  1  5; P value  .227426). A mean follow-up period of 11.8 months was documented
(range, 71 to 24 months). Seven patients were lost to follow-up at less than 30 days.
Conclusion: Percutaneous thrombin injection of iatrogenic pseudoaneurysms is an effective treatment. Not only is it
minimally painful, but it can be done as an outpatient procedure and anticoagulation therapy does not hinder the success.
Minimal thrombin seems necessary to successfully treat pseudoaneurysms that may further limit procedure-related
complications. (J Vasc Surg 2002;36:779-82.)
The incidence rate of femoral pseudoaneurysms has
been documented between 0.05% and 4% but may increase
up to 16% with more complex procedures that necessitate
larger sheaths.1-4 With the increased number of percutane-
ous interventions via femoral artery cannulation, the inci-
dence rate of iatrogenic pseudoaneurysms has also in-
creased. This has resulted in the development of alternative
treatments for femoral pseudoaneurysms repair.
Open surgical repair was the gold standard for iatro-
genic pseudoaneurysms until 1991. Fellmeth et al5 re-
ported on ultrasound scan–guided compression (UGCR),
a nonsurgical intervention, for femoral pseudoaneurysms.
UGCR proved to be a beneficial nonoperative technique
for femoral pseudoaneurysms; however, it was painful for
the patient and time consuming. UGCR had decreased
success with larger pseudoaneurysms, those lasting greater
than 2 weeks in duration, and those in patients who were
undergoing anticoagulation therapy. Ultrasound scan–
guided thrombin injection (UGTI) was first introduced in
1986 by Cope and Zeit6 but only recently became increas-
ingly popular. Hesitation possibly stemmed from potential
intraarterial injection. Initial studies are encouraging, but
continued prospective studies will aid in demonstrating the
role of UGTI in the treatment of femoral pseudoaneu-
rysms.
PATIENTS AND METHODS
Between January 1998 and December 2000, 3734
femoral catheterizations were performed in our institution.
Thirty-three femoral pseudoaneurysms (0.88%) in 32 con-
secutive patients were treated with UGTI. Exclusion crite-
ria included pregnancy, age less than 18 years, thrombin
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allergy, or pseudoaneurysm more than 8 cm. Paraanasto-
motic pseudoaneurysms or those with active bleeding,
shown clinically or with duplex scan, were surgically re-
paired. Also, those with compression of adjacent structures
(ie, nerve, vein), evidenced by pain edema or skin necrosis,
were excluded.
Diagnostic duplex scan was done with Agilent Sonos
55000 (Agilent Technologies, Andover, Mass) with
5-MHz to 7-MHz linear array transducer. Informed con-
sent was obtained. Pedal pulses were assessed before and
after the procedure. The groin was prepared and draped in
the usual sterile fashion. Topical thrombin (Gen Trac,
Middleton, Wis) had a concentration of 1000 U/mL in the
initial five cases and then was decreased to 100 U/mL in
the remaining cases. The concentration was loaded into a
10-mL syringe with either a 21-gauge or 22-gauge spinal
needle attached. With direct ultrasound scan guidance, the
tip of the needle was placed within the pseudoaneurysm
and thrombin was slowly injected in 0.5-mL increments.
Back pressure was maintained at the syringe plunger to
prevent clotting of the needle. The injection of thrombin
was performed with ultrasound scan guidance to confirm
thrombosis of the sac and to ensure that the volume in-
jected did not exceed the volume capacity of the pseudo-
aneurysm. Overfilling of the sac could result in potential
spillage into the arterial system and promote subsequent
thrombosis. Successful resolution was visualized within
moments. Patency of the superficial femoral and profunda
arteries was assessed with duplex scan, and distal pulses with
Doppler scan evaluation. A pressure dressing was applied
for 24 hours, and the patient was kept at bed rest for 2 to 6
hours. Repeat duplex scan was performed at 24 hours for
inpatient procedures (n 17) and at 1 week for outpatient
procedures (n  15). Patients were evaluated at 30 days
and at each return visit to assess for persistent pulsatile groin
mass and the presence of distal pulses.
RESULTS
Thirty-three femoral pseudoaneurysms in 32 patients
were treated with UGTI. The patients (25 men; age range,
43 to 89 years; mean age, 69 years) had pseudoaneurysms
develop from percutaneous cardiac (n  22; 68.8%) or
peripheral (n  10; 31.2%) interventions; three of the
peripheral cases were endoluminal grafts. The patient co-
morbidities are noted in the Fig. None of the cases were
after failure of a percutaneous suture device. The pseudo-
aneurysm size ranged from a maximum diameter of 1.7 to
7.5 cm. Sheath size varied from 6F to 10F (Table). Dura-
tion of pseudoaneurysm before attempted ablation was 1 to
17 days (mean duration, 4.7 days). Forty-three percent of
the cases were treated within 2 days, and 90% within 1
week.
Thirty patients (93.8%) were undergoing systemic an-
ticoagulation therapy before the discovery of the pseudo-
aneurysm, and 21 (65.8%) continued to receive systemic
anticoagulant therapy. None had the anticoagulant therapy
reversed.
Sheath size correlation with occurrence of
pseudoaneurysms on basis of totals of femoral artery
catheterizations
Sheath size
No. of
catheterizations
No. of
occurrences
of PSAs
Percentage of PSA
occurrence
5F 272 0 0
6F 461 7 1.55
7F 1193 12 0.93
8F 1624 11 0.67
9F 107 2 1.86
10F 77 1 1.02
Totals 3734 33 0.88
4F and 11 to 14F not included.
2: degrees of freedom, 6–1  5; P value, .227426. P value obtained is not
less than .05 and therefore not statistically significant.
PSA, Pseudoaneurysm
Patient comorbidities. CAD, Coronary artery disease; HTN, hypertention; PVOD, peripherovascular occlusive disease;
DM, diabetes mellitus; CHF, congestive heart failure; CVA, cerebrovascular accident.
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Initial success was seen with all 33 pseudoaneurysms
(100%). Each case was injected on a single occasion. The
volume of thrombin used ranged from 0.5 to 6.0 mL (mean
volume, 2.3 mL). The 30-day success rate was 93.9%, with
the recurrence of two pseudoaneurysms. No vascular com-
plications, including thrombosis of distal vessels, occurred.
No mortality occurred.
Recurrence of the pseudoaneurysm occurred in two of
the 33 cases (6.1%), documented with duplex scan postpro-
cedurally at day 1 and day 8, respectively. Both of these
patients were obese and had chronic obstructive pulmonary
disease (COPD). Both patients had had recent cardiac
interventions and were taking antiplatelet agents. One pa-
tient had a failed second attempt at thrombin injection and
had groin cellulitis develop, and hence, the vessel was
repaired surgically. The other patient underwent repeat
imaging before discharge, with successful thrombosis doc-
umented. Eight days later, this patient was readmitted with
worsening lower extremity swelling. The groin was imaged
to rule out deep venous thrombosis, and the pseudoaneu-
rysm and a large hematoma were identified. This patient’s
hemoglobin level had decreased, and therefore, open sur-
gical repair was selected. Twenty of the 21 patients (95.2%)
who continued to receive systemic anticoagulation had
successful ablation of their pseudoaneurysm. The one fail-
ure of the anticoagulated group (30 patients) was the
pseudoaneurysm recurrence at day 1 in the patient with
groin cellulitis.
Successful ablation was independent of pseudoaneu-
rysm size or duration. No correlation was found between
successful resolution of the pseudoaneurysm and the
amount, or concentration, of thrombin injected. The min-
imal amount of thrombin necessary was 100 international
units (IU). No statistical significance was found between
the occurrence of the pseudoaneurysm and the sheath size
used (with 2 test, P value  .227426). Fifteen of the 17
hospitalized patients (88.2%) were discharged on day 1 or 2
after the UGTI. The two remaining patients were dis-
charged on day 8, after resolution of a gastrointestinal
bleed, and on day 9, after open surgical repair for pseudo-
aneurysm recurrence at day 1. The patient readmitted for
late recurrence (day 8) was hospitalized for 8 days for
unrelated medical reasons. Fifteen patients underwent
UGTI on an outpatient basis with 100% success. No patient
had significant periprocedural pain or discomfort, which
was managed when necessary with intravenous medications
as deemed by the caregiver (vascular surgeon or physician
assistant). A mean follow-up period of 11.8 months was
completed (range, 1 to 24 months). Seven patients were
lost to follow-up at less than 30 days.
DISCUSSION
Open surgical repair was the gold standard for iatro-
genic pseudoaneurysms until 1991. Fellmeth et al5 and
Cox et al7 reported on UGCR, a nonsurgical intervention,
for femoral pseudoaneurysms. UGCR proved to be a ben-
eficial nonoperative technique for femoral pseudoaneu-
rysms; however, it was painful for the patient and time
consuming and had limited success with anticoagulation
therapy and larger pseudoaneurysms. UGTI was first intro-
duced by Cope and Zeit6 in 1986 but only recently has
become increasingly popular. With UGTI, Liau et al8 suc-
cessfully treated five pseudoaneurysms in 1997, and the
following year, Kang et al9 showed a 95% success rate in 21
cases. In March 2000, Kang et al10 published a series of 83
pseudoaneurysms (74 femoral) with an overall success of
96%. Most recently, Sackett et al11 published a series of 30
UGTI with 1000 U/mL of thrombin and documented a
90% success rate and a 3% morbidity rate. Most of the past
studies used 1000 IU/mL with each attempt at pseudoan-
eurysm thrombosis.
We showed increased success with UGTI compared
with that of compression of larger pseudoaneurysms and
those in patients undergoing anticoagulation therapy. No
correlation was found between the size of the pseudoaneu-
rysm and successful thrombosis (point biserial correlation, t
 0.1416). Anticoagulation therapy did not impair the
success compared with UGCR.7,12-14 Twenty of the 21
patients (95.2%) who continued to receive systemic antico-
agulation had successful ablation of their pseudoaneurysm.
The one failure of the anticoagulated group (30 patients)
was the pseudoaneurysm recurrence at day 1 in the patient
with groin cellulitis. We cannot comment whether there
was increased success of longstanding pseudoaneurysms
because the oldest one in our series was only present 17
days.
Early recurrence was minimal (6.1%). No late recur-
rence was documented with a mean follow-up period of
11.8 months. Of the two recurrences, a possible factor
contributing to failure may have been increased intraab-
dominal pressure from severe COPD. Also, both patients
were obese. The Fig documents patient comorbidities. Of
the five patients with COPD, 40% (n  2) had recurrent
pseudoaneurysms develop, and of the four who were obese,
50% (n 2) had recurrent pseudoaneurysms. No statistical
significance was found between the occurrence of the pseu-
doaneurysm and size of sheath used (with 2 test, P value
0.227426; Table).
A trend toward minimal medication is a striking obser-
vation in our series. The amount of volume injected into
the femoral pseudoaneurysms can be increased while the
low concentration is maintained. Past series have injected
different amounts of thrombin concentrations with low
volumes (ie, tuberculin syringes9), with a possible repeat of
the injection if the initial attempt failed. In 10 of the last 11
cases, less than 800 IU of thrombin was necessary to
successfully ablate the pseudoaneurysm. We found that
volume besides concentration played an important role in
larger pseudoaneurysms. As little as 100 IU was necessary
in three pseudoaneurysms, and 200 IU in an additional
seven pseudoaneurysms. Further research is necessary to
determine whether the volume of thrombin injected rather
than concentration is what correlates with successful
thrombosis. The volume injected should never exceed the
volume of the pseudoaneurysm because of potential spill-
age into the arterial system and subsequent thrombosis.
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Lastly, UGTI is a cost-effective approach to iatrogenic
femoral pseudoaneurysm ablation. A vial of 10,000 IU of
thrombin is approximately $40.00. The costs of the ultra-
sound scan and actual procedure are estimated at $300.00
and $150.00, respectively. Thus, the total cost of UGTI is
nearly $500.00. Open surgical repair of the artery is esti-
mated at $980.00. Evacuation of a hematoma is as much as
$690.00. These costs do not include the cost of anesthesia
($2000.00) or the hospitalization ($1000.00/day). These
cost estimates overwhelming show UGTI to be a cost-
effective treatment.
CONCLUSION
UGTI is a safe treatment of iatrogenic femoral
pseudoaneurysms that has excellent results with little asso-
ciated morbidity. UGTI is less painful and less time con-
suming than the previously used UGCR.
UGTI can be performed on an outpatient basis, which
makes it a less costly approach to pseudoaneurysms than
open surgical repair. Anticoagulation therapy is not a con-
traindication nor does it limit the success of UGTI. Lastly,
successful thrombosis can be achieved with minimal
amounts of thrombin, possibly limiting potential proce-
dural morbidity.
REFERENCES
1. Messina LM, Brothers TE, Wakefield TW, Zelenock GB, Lindenauer
SM, Greenfield LJ, et al. Clinical characteristics and surgical manage-
ment of vascular complications in patients undergoing cardiac catheter-
ization: interventional versus diagnostic procedures. J Vasc Surg 1991;
13:593-600.
2. Kresowik TF, Khoury MD, Miller BV, Winniford MD, Shamma AR,
Sharp WJ, et al. A prospective study of the incidence and natural history
of femoral vascular complications after transluminal coronary angio-
plasty. J Vasc Surg 1991;13:328-36.
3. Ricci MA, Trevisani GT, Pilcher DV. Vascular complications of cardiac
catheterization. Am J Surg 1994;167:375-8.
4. Lumsden AB, Miller JM, Kosinski AS, Allen RC, Dodson TF, Salam
AA, et al. A prospective evaluation of surgically treated groin complica-
tions following percutaneous cardiac procedures. Am Surg 1994;60:
132-7.
5. Fellmeth BD, Roberts AC, Bookstein JJ, Freischlag JA, Forsythe JR,
Buckner NK, et al. Postangiographic femoral artery injuries: non-
surgical repair with ultrasound guided compression. Radiology 1991;
178:671-5.
6. Cope C, Zeit R. Coagulation of aneurysms by direct percutaneous
thrombin injection. AJR Am J Roentgenol 1986;147:383-7.
7. Cox GS, Young JR, Gray BR, Grubb MW, Hertzer NR. Ultrasound-
guided compression repair of postcatheterization psuedoaneursyms:
results of treatment in one hundred cases. J Vasc Surg 1994:19:683-6.
8. Liau CS, Ho FM, Chen MF, Lee YT. Treatment of iatrogenic femoral
artery pseudoaneurysm with percutaneous thrombin injection. J Vasc
Surg 1997;26:18-23.
9. Kang SS, Labropoulos N, Mansour MA, Baker WH. Percutaneous
ultrasound-guided thrombin injection: a new method for treating post-
catheterizarion femoral pseudoaneurysms. J Vasc Surg
1998;27:1032-8.
10. Kang SS, Labropoulos N, Mansour MA, Michelini M, Filliung D,
Baubly MP, et al. Expanded indications for ultrasound-guided throm-
bin injection of pseudoaneursyms. J Vasc Surg 2000;31:289-96.
11. Sackett WR, Taylor SM, Coffey CB, Viers KD, Langan EM III, Cull
DL, et al. Ultrasound-guided thrombin injection of iatrogenic femoral
pseudoaneurysms: a prospective analysis. Am Surg 2000;66:937-40.
12. Hajarizadeh H, LaRosa CR, Cardullo P, Rohrer MJ, Cutler BS. Ultra-
sound-guided compression of iatrogenic femoral pseudoaneurysm fail-
ure, recurrence, and long-term results. J Vasc Surg 1995;22:425-30.
13. Coley BD, Roberts AC, Fellmeth BD, Valji K, Bookstein JJ, Hye RJ.
Postangiographic femoral artery pseudoaneurysms: further experience
with US-guided compression repair. Radiology 1995;194:307-11.
14. Hodgett DA, Kang SS, Baker WH. Ultrasound-guided compression
repair of catheter-related femoral artery pseudoaneurysms is impaired
by anticoagulation. Vasc Surg 1997;31:639-44.
Submitted Nov 29, 2001; accepted Apr 12, 2002.
JOURNAL OF VASCULAR SURGERY
October 2002782 Olsen et al
